Mayor Michelle Wu will unveil a public‑private partnership at Eliot Upper School aimed at making Boston Public Schools a national leader in K‑12 AI literacy. The plan emphasizes classroom curriculum, teacher training and private‑sector support.

Cambridge Mobile Telematics raised $350M from TPG, Allianz and State Farm to expand in Europe and scale AI crash-detection while adding engineering roles in Cambridge.

Pfizer and Valneva say their VLA15 Lyme vaccine is showing promise in late‑stage trials; a Phase 3 readout is expected in early 2026.

Quotient Therapeutics, a Flagship spinout in Cambridge, struck a potential $2.2B partnership with Merck to mine somatic genomes for inflammatory bowel disease targets.

Abbott has closed its roughly $21B purchase of Exact Sciences, paying $105 a share and folding Cologuard and other cancer‑testing assets into its diagnostics arm while keeping Exact’s Madison operations intact.

An international drilling mission found low‑salinity water trapped beneath the Atlantic off New England. Early estimates say the supply could be huge — but tapping it would be complex.

Merlin Labs went public this week via a SPAC merger, listing on Nasdaq under MRLN and closing at $9.03. The Boston startup arrives with fresh capital and a $105M defense contract to accelerate hiring and certification.

Mass General Brigham used AI to re‑read routine CTs and found thymus health may predict disease risk and responses to immunotherapy. The finding is promising but needs trial validation.

Aldeyra’s shares plunged about 70% after the FDA declined to approve reproxalap, the Lexington biotech’s lead dry‑eye candidate.

WPI researchers say an AI model flagged Alzheimer’s‑linked brain volume loss in hundreds of MRIs with about 93% accuracy and uncovered age‑ and sex‑specific patterns. The team is testing follow‑ups.

MIT researchers traced leaky brain vessels in Rett syndrome to miR‑126‑3p; an anti‑miR drug currently in leukemia trials could offer an early path to therapy.

Stanford and other U.S. hospitals are testing CAR‑T as a one‑time treatment for progressive MS. Early data show immune effects but safety and repair of old damage remain uncertain.

Mass General Brigham landed a $50 million anonymous gift to expand gene and cell therapy research and clinical trials across the system.